Director Parshall trims Cytokinetics (CYTK) stake with 5,000-share sale

Rhea-AI Filing Summary

CYTOKINETICS INC director Lynne Parshall sold shares in the company. On June 1, 2026, she executed an open-market sale of 5,000 shares of Common Stock at $74.08 per share. After this transaction, she directly holds 15,784 shares of Cytokinetics common stock.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares ($370,400)

Net Sell 1 txn

Insider PARSHALL B LYNNE

Role null

Sold 5,000 shs ($370K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,000	$74.08	$370K

Holdings After Transaction: Common Stock — 15,784 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 5,000 shares Sale price per share: $74.08 per share Shares owned after transaction: 15,784 shares

3 metrics

Shares sold 5,000 shares Open-market sale of Cytokinetics Common Stock on June 1, 2026

Sale price per share $74.08 per share Price for the 5,000 Cytokinetics shares sold

Shares owned after transaction 15,784 shares Director Lynne Parshall’s direct holdings following the sale

Key Terms

open-market sale, Common Stock, Form 4

3 terms

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PARSHALL B LYNNE

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S		5,000	D	$74.08	15,784	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Ms. Parshall	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cytokinetics (CYTK) disclose for Lynne Parshall?

Cytokinetics disclosed that director Lynne Parshall sold 5,000 shares of Common Stock in an open-market transaction on June 1, 2026 at a price of $74.08 per share.

How many Cytokinetics (CYTK) shares did Lynne Parshall sell and at what price?

Director Lynne Parshall sold 5,000 shares of Cytokinetics Common Stock at $74.08 per share. The Form 4 identifies this as an open-market sale under transaction code “S.”

How many Cytokinetics (CYTK) shares does Lynne Parshall own after the sale?

Following the reported transaction, director Lynne Parshall directly owns 15,784 shares of Cytokinetics Common Stock. This post-transaction holding figure comes directly from the Form 4 ownership data.

Was the Cytokinetics (CYTK) insider trade by Lynne Parshall a buy or a sell?

The Form 4 shows a sell transaction by director Lynne Parshall. It is coded “S” and described as an open-market sale of 5,000 shares at $74.08 per share.

Is Lynne Parshall’s Cytokinetics (CYTK) transaction classified as direct or indirect ownership?

The reported holdings for Lynne Parshall after the sale are classified as direct ownership. The Form 4 lists the ownership code as “D,” indicating shares held directly rather than through an intermediary entity.